Beijing SL Pharmaceutical Co Ltd Capital Reinvestment Ratio
Beijing SL Pharmaceutical Co Ltd capital reinvestment ratio. Beijing SL Pharmaceutical Co Ltd (002038) has a Capital Reinvestment Ratio of 0.17x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥66.55 Million) in capital expenditures (CN¥11.35 Million). Check Beijing SL Pharmaceutical Co Ltd (002038) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Beijing SL Pharmaceutical Co Ltd (2003–2025)
Capital reinvestment ratio of Beijing SL Pharmaceutical Co Ltd from 2003 to 2025. This chart tracks Beijing SL Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 23 annual periods. Also explore net asset growth rate of Beijing SL Pharmaceutical Co Ltd to track the company's year-over-year net asset growth rate.
Beijing SL Pharmaceutical Co Ltd Capital Reinvestment Ratio by Year (2003–2025)
Beijing SL Pharmaceutical Co Ltd capital reinvestment ratio by year from 2003 to 2025. For the full cash flow conversion analysis, see 002038 cash generation efficiency.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.75x | CN¥257.66 Million | CN¥192.97 Million | ▼ -51.4% |
| 2024 | 1.54x | CN¥225.49 Million | CN¥347.38 Million | ▲ +224.7% |
| 2023 | 0.47x | CN¥460.20 Million | CN¥218.36 Million | ▲ +13.1% |
| 2022 | 0.42x | CN¥389.82 Million | CN¥163.49 Million | ▼ -17.7% |
| 2021 | 0.51x | CN¥464.63 Million | CN¥236.91 Million | ▼ -17.2% |
| 2020 | 0.62x | CN¥415.84 Million | CN¥255.95 Million | ▲ +50.2% |
| 2019 | 0.41x | CN¥665.83 Million | CN¥272.78 Million | ▼ -12.6% |
| 2018 | 0.47x | CN¥485.17 Million | CN¥227.37 Million | ▼ -22.3% |
| 2017 | 0.60x | CN¥380.72 Million | CN¥229.65 Million | ▲ +45.8% |
| 2016 | 0.41x | CN¥396.86 Million | CN¥164.21 Million | ▲ +61.1% |
| 2015 | 0.26x | CN¥504.87 Million | CN¥129.68 Million | ▼ -20.9% |
| 2014 | 0.32x | CN¥465.00 Million | CN¥151.01 Million | ▲ +3.1% |
| 2013 | 0.32x | CN¥347.41 Million | CN¥109.48 Million | ▼ -49.3% |
| 2012 | 0.62x | CN¥398.60 Million | CN¥247.89 Million | ▲ +94.6% |
| 2011 | 0.32x | CN¥228.59 Million | CN¥73.05 Million | ▲ +76.8% |
| 2010 | 0.18x | CN¥238.13 Million | CN¥43.04 Million | ▲ +3.5% |
| 2009 | 0.17x | CN¥174.41 Million | CN¥30.46 Million | ▲ +43.7% |
| 2008 | 0.12x | CN¥194.32 Million | CN¥23.61 Million | ▼ -59.7% |
| 2007 | 0.30x | CN¥88.36 Million | CN¥26.61 Million | ▼ -73.3% |
| 2006 | 1.13x | CN¥57.55 Million | CN¥64.95 Million | ▼ -34.0% |
| 2005 | 1.71x | CN¥47.48 Million | CN¥81.24 Million | ▲ +201.6% |
| 2004 | 0.57x | CN¥31.26 Million | CN¥17.73 Million | ▲ +5.5% |
| 2003 | 0.54x | CN¥30.55 Million | CN¥16.43 Million | — |